ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Futibatinib, ESR1, & GPRC5D"
Episode Synopsis
A new FGFR inhibitor, futibatinib, is approved.
Is ESR1 mutation monitoring the next thing in HR+ metastatic breast cancer? The PADA-1 trial offers insight.
What the heck is GPRC5D (rhymes with CAR-T)?
PADA-1: https://doi.org/10.1016/S1470-2045(22)00555-1
GPRC5D CAR-T in Myeloma: https://www.nejm.org/doi/full/10.1056/NEJMoa2209900
Is ESR1 mutation monitoring the next thing in HR+ metastatic breast cancer? The PADA-1 trial offers insight.
What the heck is GPRC5D (rhymes with CAR-T)?
PADA-1: https://doi.org/10.1016/S1470-2045(22)00555-1
GPRC5D CAR-T in Myeloma: https://www.nejm.org/doi/full/10.1056/NEJMoa2209900
More episodes of the podcast OncoPharm
Bladder Cancer Updates & SC Amivantamab
18/12/2025
ASH 2025
11/12/2025
DPYD Deficiency Testing
04/12/2025
Cornucopia of Autumn Updates
26/11/2025
PGYNone: Dandelion Effect
20/11/2025
PGY1 Pathway: Road Trip!
13/11/2025
PGY2 Pathway: A Planned City
06/11/2025
Tale from the Crypt: Belantamab Mafodotin
30/10/2025
ESMO 2025
23/10/2025
IL-2
16/10/2025
In God we trust